comprehensive -WSS

comprehensive

author：Wikipedia 2025-09-30 01:02:38 - browse：95481

Illustration of a bear on a red arrow with a bull underneath pushing the arrow upward. -- biotech coverage from STAT — Adobe

This was supposed to be the year of the biotech comeback, when promising new medicines and high-dollar buyouts would reverse a sector-wide slump that dates back to 2021. Instead, biotech stocks have dramatically underperformed the broader market, and the year’s few green shoots are yet to grow into a turnaround.

The closely watched XBI biotech index has fallen more than 10% in 2023, while the S&P 500 rose about 13% in the same period. Privately held companies have struggled to raise new capital without taking a hit to their valuations, and biotech IPOs have been rare in number and inconsistent in return.

The problem, analysts and investors said, is that the generalist investors who steer trillions of dollars of capital have simply soured on biotech. The furor over novel weight loss medicines like Wegovy has largely been a Big Pharma phenomenon, and rising interest rates have steered fund managers away from risky biotech stocks. The sector has gone through boom and bust cycles in the past, and it’s difficult, if not impossible, to predict when the macro winds might change and make biotech as popular as it was in the early days of Covid-19.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Eli Lilly CEO gives to Mike Pence presidential super PAC

focus

WSS

Neurocrine congenital adrenal hyperplasia trial succeeds

What happened to the House vote on health price transparency?

Why is France rioting? What to know about the fatal police shooting of Nahel M

Doctor appointment wait times are getting worse

Meta looks to target Twitter with a rival app called Threads

Neurocrine congenital adrenal hyperplasia trial succeeds

Wikipedia

comprehensive

leisure time

Apple is now the first public company to be valued at $3 trillion

PBMs drew scrutiny in House hearing — and so did pharma

After affirmative action ruling, medical educators look to 'holistic review'

FDA weighs limits of animal data in assessing artificial wombs

Trump demands the U.S. pay no more for drugs than other countries … again

Grail is spending more than ever lobbying Congress

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Grail is spending more than ever lobbying Congress

After affirmative action ruling, medical educators look to 'holistic review'

Listen: PBM conflicts, RSV vaccines, & the future of flu season

Wikipedia

Van's Gluten Free Original Waffles recalled for possible wheat allergen

Akili changes sales model for its ADHD video game treatment

Did the public have the right to know Arthur Ashe had AIDS?

A new study asks: Are we harming blood donors by taking blood?

RaDonda Vaught case: a double standard for nurses, physicians

A new study asks: Are we harming blood donors by taking blood?

hotspot

focus

focus

Wikipedia